An Independent Reading Desk for Peptide Research

What this site is

API Peptide is a literature digest built around one organizing idea: reading research peptides as active pharmaceutical ingredients — the working molecule inside a drug — rather than as a single undifferentiated category. Four compounds sit on this site: semaglutide, tirzepatide, tesamorelin, and BPC-157. They share a broad family resemblance (each is a synthetic peptide engineered to act on an existing receptor system in the body) and almost nothing else in terms of regulatory maturity or evidence base, and this site treats that difference as the most important thing a reader can understand.

Every quantitative claim on this site — a percentage, a hazard ratio, a sample size, a duration — is cited to a specific published study or regulatory source, listed in full on the references page. Where the site describes patient- or community-reported experience, it is explicitly labeled as anecdotal and never presented as clinical evidence.

What this site is not

This is not a clinic, a pharmacy, or a vendor. Nothing on this site is for sale, and nothing here recommends a dose for any individual to take. Where a study dose is mentioned, it is reported exactly as the cited study administered it — as a description of what was tested, not as guidance for a reader. This site does not diagnose, treat, or provide medical advice, and reading it is not a substitute for talking with a licensed clinician.

How we choose what to publish

Sources cited here are peer-reviewed journal articles, registered clinical trials, and named regulatory or public-health references — the FDA, the World Anti-Doping Agency's Prohibited List, and NIH resources such as LiverTox. Community-sourced material (patient forums, drug-review sites, published qualitative research on patient experience) is used only to describe reported real-world effects, and every such passage is labeled anecdotal in the text itself, not just in a disclaimer.

Each compound's evidence base is presented at the depth the published literature actually supports — which is why the tesamorelin and BPC-157 pages are structured differently from the semaglutide and tirzepatide pages. Tesamorelin and BPC-157 do not have the same volume of controlled human data, and stretching thin evidence to fill a template would misrepresent what is actually known.

Corrections and standards

Regulatory status, drug-class categorization, and trial results change as new data are published and as agencies update guidance. If a claim on this site becomes outdated or is shown to be inaccurate, the responsible fix is to correct the page, not to quietly leave it. Readers who want to verify anything here are encouraged to follow the citation through to the original source rather than taking any single page's word for it — that is, deliberately, how this site is built to be read.